Evaluation of cytochrome p450 inhibition assays using human liver microsomes by a cassette analysis /LC-MS/MS

Drug Metabolism Letters

Volumn 4, Issue 3, 2010, Pages 120-128

  Zambon, Serenella ^a   Fontana, Stefano ^a   Kajbaf, Mahmud ^a  

^a GSK   (Italy)

Author keywords

Cytochrome P450; High throughput; Inhibition; Liquid chromatography mass spectrometry

Indexed keywords

ATORVASTATIN; CYTOCHROME P450; CYTOCHROME P450 1A2; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 3A4; DICLOFENAC; DRUG METABOLITE; FLUVOXAMINE; KETOCONAZOLE; MEPHENYTOIN; MIDAZOLAM; NIFEDIPINE; PHENACETIN; QUINIDINE; SULFAPHENAZOLE; TICLOPIDINE; ENZYME INHIBITOR; ISOENZYME;

ARTICLE; CONCENTRATION (PARAMETERS); ENZYME ASSAY; ENZYME INHIBITION; HUMAN; HUMAN CELL; IC 50; LIQUID CHROMATOGRAPHY; METABOLITE; MICROSOME; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REPRODUCIBILITY; TANDEM MASS SPECTROMETRY; BIOASSAY; DRUG ANTAGONISM; DRUG EFFECT; ENZYME SPECIFICITY; ENZYMOLOGY; HIGH THROUGHPUT SCREENING; LIVER MICROSOME; METABOLISM; METHODOLOGY; TIME; VALIDATION STUDY;

BIOLOGICAL ASSAY; CHROMATOGRAPHY, LIQUID; CYTOCHROME P-450 ENZYME SYSTEM; ENZYME INHIBITORS; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; ISOENZYMES; MICROSOMES, LIVER; REPRODUCIBILITY OF RESULTS; SUBSTRATE SPECIFICITY; TANDEM MASS SPECTROMETRY; TIME FACTORS;

EID: 78049445726     PISSN: 18723128     EISSN: None     Source Type: Journal    
DOI: 10.2174/187231210791698483     Document Type: Article

References (31)

1. Peng, S. X; Barbone, A. G.; Ritchie, D.M. High-throughput cyto-chrome P450 inhibition assays by ultrafast gradient liquid chroma-tography with tandem mass spectrometry using monolithic col-umns. Rapid Commun. Mass Spectrom., 2003, 17(6), 509-518.
2. Walsky, R.L.; Boldt, S. E. In vitro cytochrome P450 inhibition andinduction. Curr. Drug Metab., 2008, 9(9), 928-939.
3. Kennedy, T. Managing the drug discovery/development interface.Drug Dis.Today, 1997, 2, 436-444.
4. Stringer, R.; Nicklin, P.L.; Houston, J.B. Reliability of humancryopreserved hepatocytes and liver microsomes as in vitro systemsto predict metabolic clearance. Xenobiotica, 2008, 38(10), 1313-29.
5. Riley, R.J.; McGinnity, D.F.; Austin, R.P. A unified model forpredicting human hepatic, metabolic clearance from in vitro intrin-sic clearance data in hepatocytes and microsomes. Drug MetabDispos., 2005, 33(9), 1304-1311.
6. Kalra, B.S. Cytochrome P450 enzyme isoforms and their therapeu-tic implications: An update. Indian J. Med. Sci., 2007, 61(20), 102-116.
7. Mitschke, D.; Reichel, A.; Fricker, G.; Moenning, U. Characteriza-tion of cytochrome P450 protein expression along the entire lengthof the intestine of male and female rats. Drug Metab.Dispos., 2008,36(6), 1039-1045.
8. Willian, J.A.; Hyland, R.; Jones, B.C.; Smith, D.A.; Hurst, S.; Goosen, T.C.; Peterkin, V.; Koup, J.R.; Ball, S.E. Drug-drug in-teractions for UDP-glucuronosyltransferase substrate: A pharma-cokinetic explanation for typically observed low exposure(AUCI/AUC) ratios. Drug Metab. Dispos., 2004, 32(11), 1201-1208.
9. Fowler, S.; Zhang, H. In vitro evaluation of reversible and irre-versible cytochrome P450 inhibition: current status on methodolo-gies and their utility for predicting drug-drug interactions. AAPS J.,2008, 10(2), 410-424.
10. Bertz, R.J.; Granneman, G.R. Use of in vitro and in vivo data toestimate the likelihood of metabolic pharmacokinetic interactions.Clin. Pharmacokinet., 1997, 32, 210-258.
11. Testino, Jr. S.A.; Patonay, G. High-throughput inhibition screen-ing of major human cytochrome P450 enzymes using an in vitrococktail and liquid chromatography-tandem mass spectrometry. J.Pharm. Biomed. Anal., 2003, 30, 1459-1467.
12. Obach, R.S.; Walsky, R.L.; Venkatakrishnan, K.; Houston, J.B.; Tremaine, L.M. In vitro cytochrome P450 inhibition data and theprediction of drug-drug interactions: Qualitative relationships,quantitative predictions, and the rank-order approach. Clin. Phar-macol. Therapeut., 2005, 78, 582-592.
13. Obach, R.S.; Walsky, R.L.; Venkatakrishnan, K.; Gaman, E.A.; Houston, J.B.; Tremaine, L.M. The utility of in vitro cytochromeP450 inhibition data in the prediction of drug-drug interactions. J.Pharmacol. Exp. Ther., 2006, 316, 336-348.
14. Huang, S.; Lesko, L.; Williams, R. Assessment of the quality andquantity of drug-drug interaction studies in recent NDA submis-sions: study design and data analysis issues. J. Clin. Pharmacol.,1999, 39, 1006-1014.
15. Mouly, S.; Meune, C.; Bergmann, J.F. Mini-series: I. Basic science.Uncertainty and inaccuracy of predicting CYP-mediated in vivodrug interactions in the ICU from in vitro models: focus onCYP3A4. Intensive Care med., 2009, 35, 417-429.
16. Li, Di.; Kerns, E.H.; Li, S.L.; Carter, G.T.; Comparison of cyto-chrome P450 inhibition assays for drug discovery using humanliver microsomes with LC-MS, rhCYP450 isozymes with fluores-cence, and double cocktail with LC-MS. Int. J. Pharm., 2007,335(1-2), 1-11.
17. Yao, M.; Zhu, M.; Sinz, M.W.; Zhang, H.; Humphreys, W.G.; Rodrigues, A.D.; Dai, R. Development and full validation of sixinhibition assays for five major cytochrome P450 enzymes in hu-man liver microsomes using an automated 96-well microplate in-cubation format and LC-MS/MS analysis. J. Pharm. Biomed.Anal., 2007, 44(1), 211-223.
18. Ayrton, J.; Plumb, R.; Leavens, W. J.; Mallett, D.; Dickins, M.; Dear, G. J.; Application of a generic fast gradient liquid chroma-tography tandem mass spectrometry method for the analysis of cy-tochrome P450 probe substrates. Rapid Commun. Mass Spectrom.,1998, 12(5), 217-224.
19. Dierks, E.A.; Stams, K.R.; Lim, H.K.; Cornelius, G., Zhang, H.; Ball, S.E. A Method for the Simultaneous evaluation of the activi-ties of seven major human drug-metabolizing cytochrome P450susing an in Vitro cocktail of probe substrates and fast gradient liq-uid chromatography tandem mass spectrometry. Drug Metab. Dis-pos., 2001, 29(1), 23-29.
20. Yin, H. B.; Racha, J.A.; Li, S.-Y.B.; Olejnik, N.A.; Satoh, H.A.; Moore, D. Automated high throughput human CYP isoform acti-vity assay using SPE-LC/MS method: application in CYP inhibi-tion evaluation. Xenobiotica, 2000, 30(2), 141-154.
21. Crespi, C.L.; Miller, V.P.; Penman, B.V. Microtiter plate assaysfor inhibition of human, drug-metabolizing cytochromes P450.Anal. Biochem., 1997, 248(1), 188-190.
22. Bu, H.Z.; Magis, L.; Knuth, K.; Teitelbaum, P. High-throughputcytochrome P450(CYP) inhibition screening via a cassette probe-dosing strategy. VI. simultaneous evaluation of inhibition potentialof drugs on human hepatic isozymes CYP2A6, 3A4, 2C9, 2D6 and2E1. Rapid Commun. Mass Spectrom, 2001, 15, 741-748.
23. Smith, D.; Sadagopan, N.; Zientek, M.; Reddy, A.; Cohen, L. Analytical approaches to determine cytochrome P450 inhibitorypotential of new chemical entities in drug discovery. J. Chroma-togr. B, 2007, 850(1-2), 455-463.
24. He, F.; Bi, H.C.; Xie, Z.Y.; Zuo, Z.; Li, J.K.; Li, X.; Zhao, L.Z.; Chen, X.; Huang, M. Rapid determination of six metabolites frommultiple cytochrome P450 probe substrates in human liver micro-some by liquid chromatography/mass spectrometry: application tohigh-throughput inhibition screening of terpenoids. Rapid Com-mun. Mass Spectrom., 2007, 21(5), 635-643.
25. Zhang, L.; Wei, M.Y.; Zhao, C.Y.; QI, H.M. Determination of theinhibitory potential of 6 fluoroquinolones on CYP1A2 andCYP2C9 in human liver microsomes. Acta Pharmacol. Sinica,2008, 29(12), 1507-1514.
26. Gómez-Lechón, M.J.; Castell, V.; Donato, M.T. An update onmetabolism studies using human hepatocytes in primary culture.Expert Opin. Drug Metab. Toxic., 2008, 4(7), 837-854.
27. Samuel, A.; Testino, Jr.; Gabor, P. High-throughput inhibitionscreening of major human cytochrome P450 enzymes using an invitro cocktail and liquid chromatography-tandem mass spectrome-try. J. Pharm. Biomed. Anal., 2003, 30, 1459-1467.
28. Youdim, K.A.; Lyons, R.; Payne, L.; Jones, B.C.; Saunders, K. Anautomated, high-throughput, 384 well Cytochrome P450 cocktailIC50 assay using a rapid resolution LC-MS/MS end-point. J.Pharm. Biomed. Anal., 2008, 48, 92-99.
29. Zientek, M.; Miller, H.; Smith, D.; Dunklee, M.B.; Heinle, L.; Thurston, A.; lee, C.; Hyland, R.; Fahmi, O.; Burdette, D.Development of an in vitro drug-drug interaction assay to simulta-neously monitor five cytochrome P450 isoforms and performanceassessment using drug library compounds. J. Pharmacol. Toxicol.Method.,2008, 58(3), 206-214.
30. Hickman, D.; Wang, J.P.; Wang, Y.; Unadkat, J.D. Evaluation ofthe selectivity of in vitro probes and suitability of organic solventsfor the measurement of human cytochrome P450 monooxygenaseactivities. Drug Metab. Dispos., 1998, 26(3), 207-215.
31. Busby, W.F.; Ackermann, J.M. Crespi, C.L. Effect of methanol,ethanol, dimethyl sulfoxide, and acetonitrile on in vitro activities ofcDNA-expressed human cytochromes P-450. Drug Metab. Dis-pos., 1999, 27(2), 246-249.